

## DAFTAR PUSTAKA

- Akaza, H., Hinotsu, S., Cooperberg, M.R., 2013. Sixth joint meeting of J-CaP and CaPSURE a multinational perspective on prostate cancer management and patient outcomes. *Japanese Journal of Clinical Oncology*, 43:56–66.
- Banyard, J., Chung, I., Wilson, A. M., Vetter, G., Le Béhec, A., Bielenberg, D. R., & Zetter, B. R., 2013. Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. *Scientific reports*, 3: 3151.
- Bartel, D. P., 2009. MicroRNA Target Recognition and Regulatory Functions. *Cell*, 136(2) :215–233.
- Bruwer, G., Heyns, C., Allen, F., 1999. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. *Eur Urol*, 35: 223–227.
- Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., Croce, C.M., 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, 99(24):15524-15529.
- Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., Croce, C.M., 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc. Natl. Acad. Sci. USA*, 101(9) : 2999–3004.
- Camussi, G., Deregibus, M.C., Bruno, S., Cantaluppi, V., Biancone, L., 2010. Exosomes/microvesicles as a mechanism of cell-to-cell communication. *Kidney International*, 78 (9) : 838-848.
- Charan, J., & Biswas, T., 2013. How to calculate sample size for different study designs in medical research?. *Indian journal of psychological medicine*, 35(2), 121-6.
- Cheng, L., Montironi, R., Bostwick, D.G., Lopez-Beltran, A., Berney, D.M., 2012. Staging of prostate cancer. *Histopathology*, 60(1): 87–117.
- Chmelar, R., Buchanan, G., Need, E.F., Tilley, W., Greenberg, N.M., 2007. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. *Int J Cancer*, 120 (4) :719–733.
- Choi J.D., & Lee J.S., 2013. Interplay between Epigenetics and Genetics in Cancer. *Genomic inform*, 11(4):164-173.
- Coller, J., & Parker, R., 2005. General translational repression by activators of mRNA decapping. *Cell*, 122 (6) : 875-886.
- Davalos, V., & Esteller, M., 2010. MicroRNAs and cancer epigenetics: a macroevolution. *Curr. Opin. Oncol*, 22 (1): 35–45.
- De Craene, B., & Berx, G., 2013. Regulatory networks defining EMT during cancer initiation and progression. *Nat Rev Cancer*, 13 (2) :97–110.

- Denli, A.M., Tops, B.B., Plasterk, R.H., Ketting, R.F., Hannon, G.J., 2004. Processing of primary the Microprocessor complex. *Nature*, 432 (7015) : 231–235.
- Ferlay,J., Soerjomataram, I., Ervik, M., 2015 .GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.11. *International Journal of Cancer*, 136 (5) : 359-386.
- Gandaglia, G., Abdollah, F., Schiffmann, J., Trudeau, V., Shariat, S.F., Kim, S.P., Perrotte, P., Montorsi, F., Briganti, A., Trinh, Q.D., Karakiewicz, P.I., Sun, M., 2014. Distribution of Metastatic Sites in Patients With Prostate Cancer:A Population-Based Analysis. *The Prostate*, 74 (2) :210-216. .
- GLOBOCAN, 2012, *Prostate Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012*. <<http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp>> (Diakses 14 Juli 2018 )
- Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., Shiekhattar, R., 2004. The Microprocessor complex mediates the genesis of microRNAs. *Nature*, 432(2014):235–240.
- Guil, S., & Esteller, M., 2009. DNA methylomes, histone codes and miRNAs:tying it all together. *Int. J. Biochem. Cell Biol*, 41(1) : 87–95.
- Gu, Y., Lei, D., Qin, X., Chen, P., Zou, Ym., 2015. Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer. *PLOS ONE*, 10(10): e0140862.
- Humphries, B., & Yang, C., 2015. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. *Oncotarget*, 6(9) : 6472–6498.
- Hutvagner, G., McLachlan, J., Pasquinelli, A.E., Balint, E., Tuschl, T. And Zamore, P.D., 2001. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. *Science* 293(5531) : 834–838.
- Ikatan Ahli Urologi Indonesia, 2011. *Guidelines on Prostate Cancer Management of the Indonesian Urological Association*. Jakarta: *Indonesian Urological Association*. ISBN: 978-979-25-4288-2.
- Kementerian Kesehatan RI, 2013, *Riskesmas 2013*. <<http://www.depkes.go.id/resources/download/general/Hasil%20Riskesmas%202013.pdf>>. (diakses 9 Juli 2018).
- Kim, J., Wu, L., Zhao, J. C., Jin, H. J., & Yu, J., 2014. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. *Oncogene*, 33(44): 5183-92.
- Komite Penanggulangan Kanker Nasional, 2014. *Panduan Penatalaksanaan Kanker Prostat*. <<http://kanker.kemkes.go.id/guidelines/PPKProstat.pdf>>. (diakses 14 Juli 2018).
- Kong, Y. W., Cannell, I. G., de Moor, C. H., Hill, K., Garside, P.G., Hamilton, T. L., Meijer, H. A., Dobbyn, H. C., Stoneley, M., Spriggs, K. A., Willis, A. E., Bushell, M., 2008. The mechanism of micro-RNA mediated translation repression is determined by the promoter of the target gene. *Proc. Natl. Acad. Sci. USA*, 105(26) : 8866-8871.

- Kozera, B., & Rapacz, M., 2013. Reference genes in real-time PCR. *Journal of applied genetics*, 54(4), 391-406.
- Kumar.S., Nag.A., Mandal.C.C., 2015. A Comprehensive Review on miR-200c, A Promising Cancer Biomarker. *Curr Drugs Target*, 16 (12):1381-1403.
- Kyoto Encyclopedia of Genes and Genome (KEGG), 2017, *Prostate cancer Reference pathway*, <[https://www.genome.jp/kegg-bin/show\\_pathway?hsa05215](https://www.genome.jp/kegg-bin/show_pathway?hsa05215)> (diakses 29 November 2018)
- Lamouille, S., Xu, J., Derynck, R., 2014. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol*, 15(3):178–196.
- Lee, F., Torp-Pedersen, S.T., Siders, D.B., Littrup, P.J., McLeary, R.D., 1989. Transrectal ultrasound in the diagnosis and staging of prostate cancer. *Radiology*, 170(3 Pt 1):609-15.
- Lee, S. H., & Shen, M. M., 2015. Cell types of origin for prostate cancer. *Current Opinion in Cell Biology*, 37 : 35–41.
- Lemeshow. S., Hosmer, D.W., Klar, J., Lwanga, S.K., and World Health Organization, 1990. Adequacy of Sample Size in Health Study.
- Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J.M., Song, J. J., Hammond, S. M., Joshua-Tor, L., Hannon, G. J., 2004. Argonaute 2 is the catalytic engine of mammalian RNAi. *Science*, 305 (5689):1437-1441.
- Livak, K.J., Schmittgen, T.D., 2001. Analysis of Relative Gene Expression Data Using Real Time Quantitative PCR and the  $2^{-\Delta\Delta CT}$  Method. *Method*, 25 (4):383-481.
- Lund, E., Guttinger, S., Calado, A., Dahlberg, J.E., Kutay, U., 2004. Nuclear export of microRNA precursors. *Science*, 303 (5654), 95–98.
- Lynch, S.M., O'Neill, K.M., McKenna, M.M., Walsh, C.P., McKenna, D.J., 2016. Regulation of miR-200c and miR-141 by Methylation in Prostate Cancer. *The Prostate*, 76(13):1146-1159.
- MacFarlane, L.A., Murphy, P.R., 2010. MicroRNA: Biogenesis, Function and Role in Cancer. *Current Genomics*, 11(7):537-561.
- Martignano, F., Gurioli, G., Salvi, S., Calistri, D., Costantini, M., Gunelli, R., De Giorgi, U., Foca, F., ... Casadio, V., 2016. GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. *Disease markers*, 4358292.
- McGregor. B., Tulloch. A., Quinlan. M., 1978. The role of bone scanning in the assessment of prostatic carcinoma. *Br J*, 50 (3) : 178–81.
- Melo, S.A., Esteller, M., 2011. Dysregulation of microRNAs in cancer: Playing with fire. *FEBS Letters*, 585(13): 2087-2099.
- miRbase, 2018, Mature sequence hsa-miR-200c-5p. [http://www.mirbase.org/cgi-bin/mature.pl?mature\\_acc=MIMAT0004657](http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0004657). (diakses 14 Juli 2018).
- Mirpath DIANATOOLS , *Pathway Viewer -Pathway 'Prostate cancer' (hsa05215)*, <<http://snf15788.vm.okeanos.grnet.gr/index.php?r=mirpath/pathwayviewer>> (diakses 28 November 2018 ).
- Mutlu, M., Raza, U., Saatci, Ö., 2016. *hsa-miR-200c : a versatile watchdog in cancer progression, EMT, and drug resistance*. *Jmol Med*, 94(6) : 629-44.

- Naeini, M.M., Ardekani, A.M., 2009. *Noncoding RNAs and Cancer. Avicenna Journal of Medical Biotechnology*, 1(2):55-70.
- National Collaborating Centre for Cancer (UK), 2014. *Prostate Cancer: Diagnosis and Treatment. Cardiff (UK): National Collaborating Centre for Cancer (UK)*. (NICE Clinical Guidelines, No. 175.) 3, Diagnosis and staging of prostate cancer. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK248396/>
- O'Donoghue. E., Constable. A., Sherwood. T., 1978. Bone scanning and plasma phosphatases in carcinoma of the prostate. *Br J Urol*, 50 (3): 172–7.
- Packer, J. R., & Maitland, N. J., 2016. The molecular and cellular origin of human prostate cancer. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1863(6):1238–1260.
- Park, S.M., Gaur, A.B., Lengyel, E., Peter, M.E., 2008. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev*,22(7):894–907.
- Parsa ,N, 2012. Environmental factors inducing human cancers. *Iran J Public Health*. 41(11):1-9.
- Pishgar,F., Ebrahimi,H., Moghaddam,S.S., Fitzmaurice,C., Amini,E, 2015 . Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the GBD Study 2015. *The Journal of Urology*, 199( 5):1224–1232.
- Puhr. M., Hoefler. J., Schäfer. G., (2012). Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of Hsa-miR-200c and miR-205. *Am J Pathol* , 181(6): 2188-201.
- Pusat Data dan Informasi Kemenkes RI , 2015 , *INFODATIN Pusat Data dan Informasi Kemenkes RI*. <<http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>>. (diakses pada 14 Juli 2018).
- Schrecengost, R. S., & Knudsen, K. E., 2013. Molecular Pathogenesis and Progression of Prostate Cancer. *Seminars in Oncology*, 40(3): 244–258.
- Sharma, S., Kelly, T.K., Jones, P.A., 2010. Epigenetics in cancer. *Carcinogenesis*, 31 (1) :27-36.
- St John, J., Powell, K., Conley-Lacomb, M. K., & Chinni, S. R., 2012. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. *Journal of cancer science & therapy*, 4(4), 94-101.
- Szczyrba, J., Nolte, E., Wach, S., 2011. Downregulation of Sec23A protein by miRNA 375 in prostate carcinoma. *Mol Cancer Res* , 9(6): 791-800.
- Szczyrba, J., Löprich, E, Wach, S., Jung, V., Unteregger, G., Barth, S., 2010. The microRNA profile of prostate carcinoma obtained by deep sequencing. *Mol Cancer Res*, 8(4) :529–38
- Tan, M. E., Li, J., Xu, H. E., Melcher, K., Yong, E., 2015. Androgen receptor: structure, role in prostate cancer and drug discovery. *Acta Pharmacologica Sinica*, 36(1) : 3–23.

- Tao, T., Liu, D., Liu, C., 2014. Autoregulatory feedback loop of EZH2/hsa-miR-200c /E2F3 as a driving force for prostate cancer development. *Biochim Biophys Acta* , 1839: 858-65.
- Umbas,R., Safriadi,F., Mochtar,C.A., Djatisoesanto,W., Rizal,A., Hamid,A.H., 2015. Urologic cancer in Indonesia. *Japanese Journal of Clinical Oncology*, 45(8):708–712.
- Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature Cell Biology*, 9(6):654-9.
- Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., Parker, R., 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev*, 20(5): 515-524.
- Velcheti, V., Karnik, S., Bardot, S. F., & Prakash, O., 2008. Pathogenesis of Prostate Cancer: Lessons from Basic Research. *The Ochsner Journal*, 8(4): 213–218.
- Ventura, A., and Jacks, T., 2009. MicroRNAs and cancer: short RNAs go a long way. *Cell*, 136 (4):586–591.
- Vlassov, A., Magdaleno, S., Setterquist, R., Conrad, R., 2012. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochimica et Biophysica Acta (BBA)*, 1820 (2012) :940-948.
- Vrba, L., Jensen, T.J., Garbe, J.C., 2010. Role for DNA methylation in the regulation of Hsa-miR-200c and miR-141 expression in normal and cancer cells. *PLoS One*, 5(1) : e8697.
- Wahid,F., Shehzad,A., Khan,T., Kim, Y.Y., 2010. MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1803 (11): 1231-1243.
- World Health Organization (WHO), 2014, *Cancer Country Profiles*. <[http://www.who.int/cancer/country-profiles/idn\\_en.pdf](http://www.who.int/cancer/country-profiles/idn_en.pdf)>. (diakses 14 Juli 2018).
- Wolff, J., Zimny, M., Borchers, H., 1998. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? *Eur Urol*, 33(4) : 376–81.
- Wu, L., Fan, J., Belasco, J. G., 2006. MicroRNAs direct rapid deadenylation of mRNA. *Proc. Natl. Acad. Sci. USA*, 103(11) : 4034-4039.
- Yi, R., Qin, Y., Macara, I.G., Cullen, B.R., 2003. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev*, 17 (24) :3011–3016.
- You, J.S., Jones, P.A., 2012. Cancer Genetics and Epigenetics: Two Sides of the Same Coin?. *Cancer Cell*, 22(1): 9–20.
- Zhang,B., Pan,X., Cobb,G.P., Anderson, T.A., 2006. microRNAs as oncogenes and tumor suppressors. *Developmental Biology*,302 (1):1-1